Home Life Sciences Peritoneal Cancer Pipeline Review, H1 2017

Peritoneal Cancer Pipeline Review, H1 2017


Peritoneal Cancer Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Peritoneal Cancer pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at


Companies Involved in Peritoneal Cancer Development are AbbVie Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Altor BioScience Corp, Amgen Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc. AstraZeneca Plc, Atara Biotherapeutics Inc etc.

The Peritoneal Cancer pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 12, 60, 36, 11, 1 and 1 respectively.

Report at


A scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer. The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritoneal Cancer therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Peritoneal Cancer therapeutics based on the mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews the latest news related to pipeline therapeutics for Peritoneal Cancer.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with the potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.


Please enter your comment!
Please enter your name here